3 results on '"Jason Y. Chew"'
Search Results
2. High-content, high-throughput analysis of cell cycle perturbations induced by the HSP90 inhibitor XL888.
- Author
-
Susan K Lyman, Suzanne C Crawley, Ruoyu Gong, Joanne I Adamkewicz, Garth McGrath, Jason Y Chew, Jennifer Choi, Charles R Holst, Leanne H Goon, Scott A Detmer, Jana Vaclavikova, Mary E Gerritsen, and Robert A Blake
- Subjects
Medicine ,Science - Abstract
BackgroundMany proteins that are dysregulated or mutated in cancer cells rely on the molecular chaperone HSP90 for their proper folding and activity, which has led to considerable interest in HSP90 as a cancer drug target. The diverse array of HSP90 client proteins encompasses oncogenic drivers, cell cycle components, and a variety of regulatory factors, so inhibition of HSP90 perturbs multiple cellular processes, including mitogenic signaling and cell cycle control. Although many reports have investigated HSP90 inhibition in the context of the cell cycle, no large-scale studies have examined potential correlations between cell genotype and the cell cycle phenotypes of HSP90 inhibition.Methodology/principal findingsTo address this question, we developed a novel high-content, high-throughput cell cycle assay and profiled the effects of two distinct small molecule HSP90 inhibitors (XL888 and 17-AAG [17-allylamino-17-demethoxygeldanamycin]) in a large, genetically diverse panel of cancer cell lines. The cell cycle phenotypes of both inhibitors were strikingly similar and fell into three classes: accumulation in M-phase, G2-phase, or G1-phase. Accumulation in M-phase was the most prominent phenotype and notably, was also correlated with TP53 mutant status. We additionally observed unexpected complexity in the response of the cell cycle-associated client PLK1 to HSP90 inhibition, and we suggest that inhibitor-induced PLK1 depletion may contribute to the striking metaphase arrest phenotype seen in many of the M-arrested cell lines.Conclusions/significanceOur analysis of the cell cycle phenotypes induced by HSP90 inhibition in 25 cancer cell lines revealed that the phenotypic response was highly dependent on cellular genotype as well as on the concentration of HSP90 inhibitor and the time of treatment. M-phase arrest correlated with the presence of TP53 mutations, while G2 or G1 arrest was more commonly seen in cells bearing wt TP53. We draw upon previous literature to suggest an integrated model that accounts for these varying observations.
- Published
- 2011
- Full Text
- View/download PDF
3. High-content, high-throughput analysis of cell cycle perturbations induced by the HSP90 inhibitor XL888
- Author
-
Leanne H. Goon, Suzanne C. Crawley, Jana Vaclavikova, Joanne I. Adamkewicz, Garth Joseph Mcgrath, Scott A. Detmer, Robert A. Blake, Jason Y. Chew, Jennifer Choi, Susan K. Lyman, Mary E. Gerritsen, Ruoyu Gong, and Charles R. Holst
- Subjects
Time Factors ,Lactams, Macrocyclic ,Science ,Phthalic Acids ,Mitosis ,Cell Cycle Proteins ,HSP90 Heat-Shock Proteins ,Synthesis Phase ,Protein Serine-Threonine Kinases ,Biology ,Cell Growth ,Cell Line ,03 medical and health sciences ,Fluorescence-Activated Cell Sorting ,0302 clinical medicine ,Proto-Oncogene Proteins ,Drug Discovery ,Molecular Cell Biology ,Basic Cancer Research ,Benzoquinones ,Humans ,Image Cytometry ,Cellular Stress Responses ,030304 developmental biology ,Genetics ,0303 health sciences ,Multidisciplinary ,Cell Cycle ,Flow Cytometry ,High-Throughput Screening Assays ,3. Good health ,High throughput analysis ,Cell staining ,Oncology ,030220 oncology & carcinogenesis ,Genome Biology ,Medicine ,Azabicyclo Compounds ,Cell Division ,Cytometry ,Research Article ,Biotechnology - Abstract
BackgroundMany proteins that are dysregulated or mutated in cancer cells rely on the molecular chaperone HSP90 for their proper folding and activity, which has led to considerable interest in HSP90 as a cancer drug target. The diverse array of HSP90 client proteins encompasses oncogenic drivers, cell cycle components, and a variety of regulatory factors, so inhibition of HSP90 perturbs multiple cellular processes, including mitogenic signaling and cell cycle control. Although many reports have investigated HSP90 inhibition in the context of the cell cycle, no large-scale studies have examined potential correlations between cell genotype and the cell cycle phenotypes of HSP90 inhibition.Methodology/principal findingsTo address this question, we developed a novel high-content, high-throughput cell cycle assay and profiled the effects of two distinct small molecule HSP90 inhibitors (XL888 and 17-AAG [17-allylamino-17-demethoxygeldanamycin]) in a large, genetically diverse panel of cancer cell lines. The cell cycle phenotypes of both inhibitors were strikingly similar and fell into three classes: accumulation in M-phase, G2-phase, or G1-phase. Accumulation in M-phase was the most prominent phenotype and notably, was also correlated with TP53 mutant status. We additionally observed unexpected complexity in the response of the cell cycle-associated client PLK1 to HSP90 inhibition, and we suggest that inhibitor-induced PLK1 depletion may contribute to the striking metaphase arrest phenotype seen in many of the M-arrested cell lines.Conclusions/significanceOur analysis of the cell cycle phenotypes induced by HSP90 inhibition in 25 cancer cell lines revealed that the phenotypic response was highly dependent on cellular genotype as well as on the concentration of HSP90 inhibitor and the time of treatment. M-phase arrest correlated with the presence of TP53 mutations, while G2 or G1 arrest was more commonly seen in cells bearing wt TP53. We draw upon previous literature to suggest an integrated model that accounts for these varying observations.
- Published
- 2011
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.